Details for Patent: 11,684,723

Which drugs does patent 11,684,723 protect, and when does it expire?

Patent 11,684,723 protects OTREXUP and is included in one NDA.

This patent has nine patent family members in five countries.

Summary for Patent: 11,684,723

Title:	Injector safety device
Abstract:	A safety member for use with an injection device is disclosed. The safety member includes a blocking ring extending into a housing of the injection device in blocking association with a latch member associated with a trigger mechanism of the injector, in which the blocking ring blocks movement of a portion of the trigger mechanism into a firing position. The safety member further includes a manipulable portion disposed outside the housing and configured for hand-manipulation by a user to remove the safety member from the housing to unblock the firing mechanism to enable firing of the injector.
Inventor(s):	Julius C. Sund, Eric Lagman, Peter A. HOEFT, Paul R. Lesch, Jr., Thomas E. Kramer
Assignee:	Antares Pharma Inc
Application Number:	US16/925,549
Patent Claim Types: see list of patent claims	Use; Dosage form;

error: insufficient information

Drugs Protected by US Patent 11,684,723

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-005	Nov 7, 2014		DISCN	Yes	No			Y
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-001	Oct 11, 2013		DISCN	Yes	No			Y
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-006	Mar 24, 2016		DISCN	Yes	No			Y
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-002	Oct 11, 2013		DISCN	Yes	No			Y

International Family Members for US Patent 11,684,723

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2718053
European Patent Office	2268342
European Patent Office	2990067
European Patent Office	3636301